Testing L-Annamycin plus Cytarabine for relapsed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether the combination of two chemotherapy drugs, L-Annamycin and Cytarabine, can help adults whose acute myeloid leukemia (AML) has come back or not responded to one prior treatment. The goal is to see if this combination can lead to remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML that has returned or not responded after just one previous treatment
- You are between 18 and 80 years old
- Your heart, liver, and kidney function are adequate based on routine tests
- You have not received another cancer treatment or experimental therapy in the last 2–4 weeks
- You are able to do most daily activities (ECOG score 0–2)
- You agree to use effective birth control if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—mitoxantrone liposome, cytarabine, and venetoclax—for people with AML that has come back or not responded to standard treatment. It aims to see if this combination is safe and effective.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
This trial tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) for patients with acute myeloid leukemia (AML) that has returned or didn't respond to prior treatments. The goal is to see if this combination can help patients achieve remission and improve survival.
This trial compares two types of chemotherapy for people with acute myeloid leukemia (AML) that came back or did not get better after initial treatment. Your doctor will help decide if you can join, and you will be randomly assigned to either a lower-intensity or a higher-intensity treatment plan.
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
Hear when a new Acute Myeloid Leukaemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.